Locations:
Search IconSearch
January 25, 2018/Neurosciences/Research

Comprehensive Vs. Primary Stroke Centers: Is There a Quality Difference?

CSCs achieve timelier acute reperfusion therapy, national study finds

Streamlined STEMI Protocol Slashes Door-to-Balloon Times

Do Comprehensive Stroke Centers really offer an advantage over Primary Stroke Centers in providing patient care?

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

According to a large new national study of stroke centers, the answer is yes, at least on a few key measures, although overall stroke care was found to be broadly similar between the two certification levels. The study was presented at the 2018 International Stroke Conference in Los Angeles. (Editor’s note: The full study was published online by Circulation: Cardiovascular Quality and Outcomes on May 23, 2018.)

“Determining whether Comprehensive Stroke Centers offer an advantage and, if so, how much of one, is important for allocating resources to optimize patient care,” says Ken Uchino, MD, Director of Research and Education for Cleveland Clinic’s Cerebrovascular Center and a co-author of the multicenter study. “Does every community need a Comprehensive Stroke Center? Does every patient with an acute stroke need to be referred to one? Such questions are worth investigating.”

The certifications at a glance

To briefly define terms, The Joint Commission provides certification to hospitals that meet standards recommended by the Brain Attack Coalition for care of acute stroke. Since 2012, two levels of certification have been offered: Primary Stroke Centers (PSCs) and Comprehensive Stroke Centers (CSCs), with the latter designation requiring an ability to provide more-complex services, including 24/7 availability of endovascular procedures.

Study design

Investigators with the current study used the American Heart Association/American Stroke Association’s Get With The Guidelines®–Stroke database to identify consecutive patients with a final diagnosis of acute ischemic stroke who were admitted to 134 CSCs (110,624 patients) and 1,047 PSCs (494,512 patients) between January 1, 2013, and December 31, 2015.

Advertisement

Multivariable regression analysis was done to explore associations between facilities’ certification level and performance measures and outcomes, after adjustment for potential confounding variables.

Key findings

CSCs were noted to be larger than PSCs, with median bed counts of 481 versus 263, respectively.

Almost all hospitals in both groups (94 percent) were found to conform with seven key performance measures, including intravenous thrombolysis among those arriving within two hours of symptom onset; use of antithrombotic medication and deep vein thrombosis prophylaxis in appropriate patients; discharge medications for atrial fibrillation and lipid lowering when indicated; and addressing smoking cessation.

However, CSCs outperformed PSCs in several key measures, especially in the use of intravenous tissue plasminogen activator (IV tPA) and intra-arterial thrombectomy (IA therapy). Among the significant differences:

  • IV tPA was administered to 14.3 percent of patients in CSCs versus 10.3 percent in PSCs (adjusted odds ratio [OR] = 1.23; 95% CI, 1.12-1.34).
  • Time from door to delivery of IV tPA was within one hour in 79.7 percent of patients in CSCs versus 65.1 percent in PSCs (adjusted OR = 1.48; 95% CI, 1.25-1.75).
  • Median time from door to IV tPA was 52 minutes in CSCs versus 61 minutes in PSCs (adjusted OR = 0.92; 95% CI, 0.89-0.95).
  • IA therapy was provided in 4.1 percent of patients in CSCs versus 1.0 percent in PSCs (adjusted OR = 2.35; 95% CI, 1.82-3.04).
  • Median time from door to IA therapy was 145 minutes in CSCs versus 152 minutes in PSCs (adjusted OR = 0.92; 95% CI, 0.87-0.98).

Advertisement

“We observed that CSCs are slightly but significantly better at providing prompt acute treatment,” says Dr. Uchino. “But overall, stroke care is similar between CSCs and PSCs, and both types of facilities are achieving good quality process measures.”

Data hide nuances

Dr. Uchino notes that there are many complexities in doing a study such as this one. Some PSCs are actually equivalent to CSCs but for various reasons have not pursued the higher certification. Others may provide thrombectomy (one of the key differences between the certification levels) but are missing other elements believed to be less critical. Such issues potentially confound the data by blurring differences between the two types of facilities.

Interestingly, the study found that in-hospital mortality was modestly higher at CSCs than at PSCs, even after adjusting for patient comorbidities (4.6 percent versus 3.8 percent; adjusted OR = 1.14; 95% CI, 1.01-1.29). According to Dr. Uchino, the current study cannot account for this difference, and he suspects other unmeasured variables may offer an explanation since it’s unlikely that the higher level of care measures at CSCs found in the study led to more deaths.

“It is critical for facilities to be transparent about their outcomes by collecting data on their performance measures and making them available for investigation and comparison,” he adds. “This is the only way we can determine if initiatives such as acute stroke care certification are important and how to further improve patient outcomes.”

Advertisement

Cleveland Clinic’s main campus hospital is a Joint Commission-certified Comprehensive Stroke Center. Cleveland Clinic health system also includes seven Primary Stroke Centers.

Advertisement

Related Articles

histopathology image with pink background and arrow pointing to round cell
New Insights on α-Synuclein Pathology and Clinical Phenotypes in Dementia With Lewy Bodies

The disease’s neuropathologic heterogeneity holds clues to refining diagnosis and prognosis

MRI of the brain against black background
Advanced Neuroimaging and Clinical Perseverance Make Sense of a 68-Year-Old’s Progressive Symptoms

A case study in pairing imaging acumen with subspecialty expertise to yield answers and symptom relief

brain scan with colored dots over a dark gray region
March 3, 2026/Neurosciences/Epilepsy
Decoding the Insula: New Semiological Insights for Localizing Seizure Onset

Guidance from the largest cohort of SEEG-confirmed insular epilepsy patients reported to date

Photo of Dr. Ford
March 2, 2026/Neurosciences/Podcast
Neuroethics Conversations: Guidelines for Care (Podcast)

Ethical guidance provides guardrails so medical advances benefit patients

red blood cells floating in a blood vessel
February 27, 2026/Neurosciences/Cerebrovascular
Factor XIa Inhibition Drives Down Recurrent Stroke Risk Without Rise in Bleeding

OCEANIC-STROKE results represent long-sought advance in secondary stroke prevention

two brightly colored brain scans side by side
February 25, 2026/Neurosciences/Epilepsy
MR Fingerprinting Shows Potential to Reshape FCD Detection and Epileptogenicity Mapping

Two studies from Cleveland Clinic may help advance the technology toward broader clinical use

MRI scan of the side of a human head
February 20, 2026/Neurosciences/Cerebrovascular
Susac Syndrome: Insights on Rare Endotheliopathy From Largest Single-Center Cohort to Date

Distinct MRI signature includes lesions beyond the corpus callosum, features predictive of vision and hearing loss

Symbolic photo illustration: stethoscope on a medical dictionary
Is ‘Atypical Parkinsonism’ a Useful Term?

An argument for clarifying the nomenclature

Ad